Home › Sakit ng Graft-versus-Host
Pag-aaral pangklinika para sa Sakit ng Graft-versus-Host na nagre-recruit sa U.S.
34 pag-aaral para sa Sakit ng Graft-versus-Host ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Boston, MA10 pag-aaral
- New York City, NY7 pag-aaral
- Columbus, OH6 pag-aaral
- Washington, DC5 pag-aaral
- Atlanta, GA5 pag-aaral
- Queens, NY4 pag-aaral
- Baldwin Park, CA4 pag-aaral
- Seattle, WA4 pag-aaral
- Tampa, FL4 pag-aaral
- Pittsburgh, PA4 pag-aaral
- Miami, FL4 pag-aaral
- Detroit, MI4 pag-aaral
- St. Louis, MO4 pag-aaral
- Portland, OR4 pag-aaral
- Houston, TX3 pag-aaral
- Staten Island, NY3 pag-aaral
- New Rochelle, NY3 pag-aaral
- Edison, NJ3 pag-aaral
- East Norwalk, CT3 pag-aaral
- Greenburgh, NY3 pag-aaral
- Los Angeles, CA3 pag-aaral
- Nashville, TN3 pag-aaral
- Chicago, IL3 pag-aaral
- Cleveland, OH3 pag-aaral
Ayos sa estado
- California9 pag-aaral
- Florida7 pag-aaral
- Georgia5 pag-aaral
- Illinois3 pag-aaral
- Kansas3 pag-aaral
- Maryland5 pag-aaral
- Massachusetts10 pag-aaral
- Michigan5 pag-aaral
- Missouri4 pag-aaral
- New Jersey4 pag-aaral
- New York10 pag-aaral
- Ohio7 pag-aaral
- Oregon4 pag-aaral
- Pennsylvania6 pag-aaral
- Tennessee3 pag-aaral
- Texas4 pag-aaral
- Washington4 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 70 · Kababaihan · Na-update Set 29, 2026 · NCT06649201Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05531786Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06910969Evaluation of Patients With Immune Function Abnormalities
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Lahat ng edad · Lahat ng kasarian · Na-update Set 22, 2026 · NCT00128973Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 7 hanggang 80 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT00106925Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT06450925Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Nagre-recruitPhase 1
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06392711Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07565220Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT00001529Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Nagre-recruitPhase 1
Edad 2 pataas · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT06991361A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07359859Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06996119A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT07006506Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06815003A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Nagre-recruitPhase 2
Edad 2 pataas · Lahat ng kasarian · Na-update Hun 16, 2026 · NCT04710576Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Nagre-recruitPhase 1/2
Edad 14 hanggang 100 · Lahat ng kasarian · Na-update May 29, 2026 · NCT05289167A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Nagre-recruitPhase 2
Edad 4 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT05675930A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 20, 2026 · NCT06615050Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Nagre-recruitPhase 2
Hanggang edad 26 · Lahat ng kasarian · Na-update May 14, 2026 · NCT07566377Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
Nagre-recruitPhase 2
Edad 2 pataas · Lahat ng kasarian · Na-update May 11, 2026 · NCT04380740Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT06008808Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06434363Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT07356245A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Nagre-recruit
Hanggang edad 30 · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT04337515Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.